CD33 and acute myeloid leukemia: CD33 (SIGLEC-3) is a member of the sialic acid-binding immunoglobulin-like lectin (Siglec) family, which has been the most exploited target in AML treatment due to its expression on at least one subset of leukemic blasts in almost all patients.